Literature DB >> 11145281

Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.

M Stolte1, M Vieth, J M Schmitz, T Alexandridis, E Seifert.   

Abstract

BACKGROUND: The application of hyperplasia of the basal cell layer and elongation of the papillae in the squamous epithelium of the distal oesophagus, as histological criteria for the diagnosis of gastro-oesophageal reflux disease (GORD), continues to be controversial. An unanswered question is whether these changes may regress under long-term treatment with proton pump inhibitors (PPI). This fact prompted us to investigate the effect of PPI treatment on the histological changes observed in the lower oesophagus.
METHODS: 295 patients with endoscopically confirmed erosive GORD were investigated by endoscopy/biopsy prior to and during the course of a 12-month PPI treatment regimen (8 weeks acute treatment with 30 mg lansoprazole/day followed by long-term treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day). The parameters studied were the frequency of ulcers and erosions and the hyperplasia of the basal cell layer and elongation of the papillae prior to treatment and on day 56 (D56), after 6 months (M6) and after 12 months (M12) of treatment.
RESULTS: In the various treatment groups, the results showed no statistically significant differences. Ulcers and erosions (prior to treatment 21% and 31%, respectively) were detected statistically significantly less frequently under PPI treatment (ulcers, D56: 1%, M6 and M12, 0%; erosions, D56: 2%, M6: 4%, M12, 3%). While high-grade hyperplasia of the basal cell layer and elongation of the papillae was found in 51% of the cases prior to treatment, the corresponding figures were only 3% (D56, M6) and 2% (M12). In contrast, the percentage of cases with normal oesophageal epithelium increased from 8% before treatment to 55% (D56), 66% (M6) and 63% (M12).
CONCLUSIONS: Our study shows not only that erosions and ulcers heal under PPI treatment, but also that hyperplasia of the basal cell layer and elongation of papillae in the squamous epithelium of the oesophageal mucosa may normalize, and are thus presumably not 'normal physiological variants'.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11145281     DOI: 10.1080/003655200750056574

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Acid challenge to the human esophageal mucosa: effects on epithelial architecture in health and disease.

Authors:  Mogens Bove; Michael Vieth; Frank Dombrowski; Lars Ny; Magnus Ruth; Lars Lundell
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

Review 2.  Lansoprazole: an update of its place in the management of acid-related disorders.

Authors:  A J Matheson; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.

Authors:  Katherine F Croom; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Investigation of relationships among gastroesophageal reflux disease subtypes using narrow band imaging magnifying endoscopy.

Authors:  Jing Lv; Dong Liu; Shi-Yang Ma; Jun Zhang
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 5.  Treatment for Barrett's oesophagus.

Authors:  Jonathan Re Rees; Pierre Lao-Sirieix; Angela Wong; Rebecca C Fitzgerald
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

6.  Direct measurement of acid permeation into rat oesophagus.

Authors:  S Tanaka; S Chu; M Hirokawa; M H Montrose; J D Kaunitz
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

Review 7.  Lansoprazole: in the management of gastroesophageal reflux disease in children.

Authors:  Lesley J Scott
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus.

Authors:  Francisco Baldaque-Silva; Michael Vieth; Mumen Debel; Bengt Håkanson; Anders Thorell; Nuno Lunet; Huan Song; Miguel Mascarenhas-Saraiva; Gisela Pereira; Lars Lundell; Hanns-Ulrich Marschall
Journal:  World J Gastroenterol       Date:  2017-05-07       Impact factor: 5.742

9.  Prospective Single Arm Study on the Effect of Ilaprazole in Patients with Heartburn but No Reflux Esophagitis.

Authors:  In Ji Song; Hyun Ki Kim; Na Keum Lee; Sang Kil Lee
Journal:  Yonsei Med J       Date:  2018-10       Impact factor: 2.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.